导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.13% | 2155/4773 |
| 近一周 | -2.16% | 1353/5462 |
| 近一月 | -3.81% | 1982/5421 |
| 近一季 | -6.69% | 2170/5209 |
| 近半年 | -1.11% | 1483/4920 |
| 近一年 | 2.69% | 2068/4366 |
| 近两年 | 48.71% | 1515/2954 |
| 近三年 | 31.51% | 992/2253 |
| 成立以来 | 195.26% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.31% 3126/4961 |
12.95% 2090/5312 |
- - |
- - |
| 2025 | 19.40% 2221/4813 |
-0.88% 2445/3635 |
2.31% 1656/4076 |
17.46% 2496/4524 |
0.24% 2105/4813 |
| 2024 | 17.84% 649/3463 |
2.89% 676/2808 |
-0.80% 841/3014 |
17.07% 1279/3129 |
-1.38% 1677/3463 |
| 2023 | -7.47% 922/2656 |
4.49% 938/2280 |
-3.49% 806/2385 |
-2.15% 624/2515 |
-6.23% 1686/2655 |
| 2022 | -17.36% 580/2207 |
-13.15% 706/1919 |
7.40% 483/2016 |
-13.07% 827/2113 |
1.92% 1084/2208 |
| 2021 | 4.46% 576/1822 |
-1.38% 482/1255 |
6.67% 730/1330 |
-3.28% 626/1466 |
2.66% 543/1822 |
| 2020 | 44.37% 227/1250 |
-7.63% 560/1028 |
16.00% 464/1067 |
16.80% 131/1164 |
15.36% 214/1184 |
| 2019 | 44.52% 169/1092 |
32.15% 178/754 |
-0.15% 228/804 |
0.61% 502/850 |
8.86% 276/918 |
| 2018 | -20.36% 191/834 |
- - |
- - |
- - |
-14.34% 579/691 |
| 2017 | 14.63% 253/714 |
- - |
- - |
- - |
- - |
| 2016 | -1.01% 116/605 |
- - |
- - |
- - |
- - |
| 2015 | -7.96% 286/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 前海开源沪深300指数A VS. 长安沪深300非周期A(740101) |